[Skip to Navigation]
Sign In
Views 580
Citations 0
Correction
September 7, 2021

Error in Figure

JAMA Neurol. 2021;78(11):1413. doi:10.1001/jamaneurol.2021.3219

In the Original Investigation titled “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies,”1 published in the February 2020 issue, the y-axis was incorrect in the Figure. The data should span 87% to 100% rather than 15% to 100%. This article has been corrected online.

References
1.
Luna  G, Alping  P, Burman  J,  et al.  Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.   JAMA Neurol. 2020;77(2):184-191. doi:10.1001/jamaneurol.2019.3365PubMedGoogle ScholarCrossref
×